Insmed | INSM - Gross Profit On Sales

Stock Price
149.86
Daily Change
-1.17 -0.77%
Monthly
-14.85%
Yearly
87.44%
Q1 Forecast
152.04

Insmed reported $111.44M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Cytokinetics USD 1.94M 64.83M Sep/2025
DBV Technologies USD 2.77M 33.21M Sep/2025
Dynavax Technologies USD 78.57M 24.17M Jun/2025
Gilead Sciences USD 5.58B 453M Jun/2025
Insmed USD 111.44M 33.36M Sep/2025
Novartis USD 10.82B 694M Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025